Sunday, May 28, 2023 | Back issues
Courthouse News Service Courthouse News Service

Pharma Merger

Directors are selling CoLucid Pharmaceuticals too cheaply through an unfair process to Eli Lilly, for $46.50 a share or $897 million, shareholders say in a federal class action.

BOSTON – Directors are selling CoLucid Pharmaceuticals too cheaply through an unfair process to Eli Lilly, for $46.50 a share or $897 million, shareholders say in a federal class action.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading...